Results 11 to 20 of about 476 (138)

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH) [PDF]

FEBS Open Bio, 2019
The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested ...
Ryo Goto, Kenya Kamimura, Yoko Shinagawa‐Kobayashi, Norihiro Sakai, Takuro Nagoya, Yusuke Niwa, Masayoshi Ko, Kohei Ogawa, Ryosuke Inoue, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Satoshi Abe, Hiroshi Nishina, Shuji Terai   +14 more
doaj   +4 more sources

Spotting the “small eyes”: using photo-ID methodology to study a wild population of smalleye stingrays (Megatrygon microps) in southern Mozambique [PDF]

PeerJ, 2019
Background The smalleye stingray (Megatrygon microps) is a large and rare dasyatid ray, patchily distributed across the Indo-West Pacific. Free-swimming individuals have regularly been recorded in Southern Mozambican coastal waters utilizing different ...
Atlantine Boggio-Pasqua, Anna L. Flam, Andrea D. Marshall   +2 more
doaj   +3 more sources

Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. [PDF]

Diabetes Obes Metab, 2022
Diabetes, Obesity and Metabolism, Volume 24, Issue 12, Page 2469-2473, December 2022.
Matsubayashi Y, Yoshida A, Suganami H, Oe M, Sato T, Yaguchi Y, Fujihara K, Yamada T, Tanaka S, Kaku K, Sone H.   +10 more
europepmc   +2 more sources

Sarcoma pleomórfico indiferenciado de alto grado/ fibrohistiocitoma maligno asociado a tofo gotoso. presentación de un caso

Revista de la Facultad de Ciencias Médicas de Córdoba, 2012
Antecedentes: La gota es una enfermedad metabólica por depósito de cristales de ácido úrico, que compromete articulaciones y tejidos blandos tanto en sus etapas agudas como crónicas.
Susana Szlabi, Jorge O. Flores, Ana L. de Diller, Marta B. Cabrera   +3 more
doaj   +2 more sources

Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss. [PDF]

Diabetes Obes Metab, 2020
Abstract Aims To investigate predictors of the initial response of beta‐hydroxybutyrate (BHB) and maximum BHB (max‐BHB) values during long‐term therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin (TOFO), and to explore the association of the initial elevation of BHB with subsequent clinical effects in people with type 2 diabetes ...
Sato Y, Nunoi K, Kaku K, Yoshida A, Suganami H.   +4 more
europepmc   +2 more sources

Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin. [PDF]

Diabetes Obes Metab, 2020
Abstract Aims Obesity and hepatic fat accumulation diminish hepatic insulin clearance, which can cause hyperinsulinaemia. Sodium/glucose‐cotransporter 2 inhibitors (SGLT2‐is) improve insulin resistance and hyperinsulinaemia by weight loss via increased urinary glucose excretion in type 2 diabetes.
Matsubayashi Y, Yoshida A, Suganami H, Osawa T, Furukawa K, Suzuki H, Fujihara K, Tanaka S, Kaku K, Sone H, Sone H.   +10 more
europepmc   +2 more sources

Reductions in liver enzymes are associated with anti-hyperglycaemic and anti-obesity effects of tofogliflozin in people with type 2 diabetes: Post-hoc analyses. [PDF]

Endocrinol Diabetes Metab
Reductions in GGT and ALT were associated with the anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin, respectively, in people with T2D. Therefore, GGT and ALT may be surrogate markers for hyperglycaemia and obesity in T2D. Abstract Aims How the pathology of type 2 diabetes (T2D), including hyperglycaemia and obesity, affects liver enzymes ...
Takamura T, Kaku K, Yoshida A, Kusakabe H, Nakamura H, Suganami H.   +5 more
europepmc   +2 more sources

Tofo gotoso

Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica, 2020
Presentamos este caso para resaltar la importancia de la identificación de los tofos gotosos en localizaciones menos clásicas, incluso en pacientes sin crisis de artritis previas, uso de terapia hipouricemiante o factores de riesgo, ya que los tofos ...
Natalia Vélez López, María Fernanda Tibaduiza, Juan David Ruiz Restrepo, Oscar Jairo Valencia Ocampo   +3 more
doaj   +2 more sources

Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. [PDF]

Diabetes Obes Metab, 2021
Abstract Sodium‐glucose cotransporter‐2 inhibitors (SGLT2) are drugs that have been reported to have several effects through the regulation of plasma volume, for example, antihypertensive effects. This study aimed to clarify the impact of long‐term administration and subsequent discontinuation of the SGLT2 inhibitor tofogliflozin on estimated plasma ...
Matsubayashi Y, Yoshida A, Suganami H, Oe M, Sato T, Yaguchi Y, Fujihara K, Yamada T, Tanaka S, Kaku K, Sone H.   +10 more
europepmc   +2 more sources

Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease. [PDF]

FEBS Open Bio, 2019
Here, we demonstrate that the highly specific sodium‐glucose cotransporter 2 inhibitor (SGLT2I) prevented the progression of nonalcoholic steatohepatitis (NASH)‐related renal injury in a medaka fish model of NASH‐related kidney disease. SGLT2I ameliorates oxidative stress and macrophage accumulation and maintained mitochondrial function in renal ...
Nagoya T, Kamimura K, Goto R, Shinagawa-Kobayashi Y, Niwa Y, Kimura A, Sakai N, Ko M, Nishina H, Terai S.   +9 more
europepmc   +2 more sources